Overstimulation of the NMDA receptors by glutamate is implicated in neurodegenerative disorders, including Alzheimer’s disease (AD) 1

The NMDA receptor antagonist memantine is approved for the treatment of moderate/severe AD alone or in combination with cholinesterase inhibitors2-4

Memantine has been shown to reduce clinical deterioration in moderate/severe AD1

Furthermore, treatment with memantine has been shown to reduce symptoms such as agitation, aggression, irritability,and appetite disturbances5

Acess our Slide Deck on treatment principles of AD and learn more about pharmacological treatment of AD.

file_download Download in HQ

Related content

image Image A multi-arm, multi-stage platform trial illustration
A multi-arm, multi-stage platform trial illustration
29.04.2025 Alzheimer’s Disease
image Image Drug Delivery Systems to the Brain
Drug Delivery Systems to the Brain

Brain drug delivery systems, allied with their characteristics for overcoming the blood-brain barrier (BBB).

29.04.2025 Alzheimer’s Disease
image Image From One-Size-Fits-All to Precision Medicine
From One-Size-Fits-All to Precision Medicine

The use of a single treatment in heterogeneous populations has proved problematic in clinical trials undertaken in patients with neurodegenerative diseases.

29.04.2025 Alzheimer’s Disease